Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

n and our financial performance.

Our actual results may vary depending on a variety of factors, including:

  • the development of competitive generic versions of oral Vancocin;
  • our ability to successfully commercialize Cinryze;
  • our ability to receive regulatory approval for the use of Cinryze for the acute treatment of HAE;
  • the availability of third party payer reimbursement for Cinryze patients;
  • our ability to develop a clinical development program for maribavir;
  • approval of products which are currently marketed for other indications by other companies or new pharmaceuticals and technological advances to treat the conditions addressed by Vancocin or Cinryze;
  • fluctuations in wholesaler order patterns and inventory levels;
  • manufacturing, supply or distribution interruptions, including but not limited to our ability to acquire adequate supplies of Vancocin and Cinryze to meet demand for the product;
  • changes in prescribing or procedural practices of physicians, including off-label prescribing of products competitive with Vancocin and Cinryze;
  • the timing of regulatory submissions and approvals;
  • actions by the FDA, EMEA and the Internal Revenue Service or other government regulatory agencies;
  • decreases in the rate of infections for which Vancocin is prescribed or decreases in the sensitivity of the relevant bacteria to Vancocin;
  • an impairment of our intangible assets if our market capitalization remains less than our book value;
  • the timing and results of anticipated events in our clinical development programs; and
  • the timing and nature of potential business development activities related to our efforts to expand our current portfolio through in-licensing or other means of acquiring produ
    '/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 27, 2014 Pressure BioSciences, Inc. (OTCQB: ... in the development and sale of high pressure-based ... market, today announced that Professor Ruedi Aebersold ... highly reproducible, and robust method to allow – ... analysis on small needle biopsy samples by mass ...
(Date:10/27/2014)... 27, 2014 Investor-Edge has initiated ... NBIX ), Insmed Inc. (NASDAQ: ... ), Dyax Corporation (NASDAQ: DYAX ), and ... companies can be accessed at: http://investor-edge.com/register . ... ended at 4,483.72, up 0.69%, the Dow Jones Industrial ...
(Date:10/26/2014)... The report "Protective Coatings Market by Resin Type, ... Forecast to 2019", defines and segments the global protective ... and value generated. The protective coatings consumption is projected ... KT by 2019, at a CAGR of 9.52% during ... and 22 figures spread through 219 slides and in-depth ...
(Date:10/25/2014)... California (PRWEB) October 23, 2014 ... a specialty pharmaceutical company devoted to bringing new ... partnerships in 2015. , ViaDerma has developed an ... allows for rapid mass transfer of pharmaceutical active ... body to provide immediate localized therapy. The transdermal ...
Breaking Biology Technology:Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 2Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 3Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 4ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3
... PhD, Further Strengthens Kendle,s Global ... Regulatory Affairs Organization, ... ), a,leading, global full-service clinical research organization, today,announced that ... Affairs Consultant specializing in providing regulatory affairs,guidance to the ...
... CORNER, N.J., Aug. 10 Reliant Pharmaceuticals,Inc. today announced ... S-1,with the Securities and Exchange Commission for an initial ... that Reliant,will sell newly issued common stock and that ... of Reliant,s common stock. Goldman, Sachs & Co. ...
... has Initiated a Phase II study of R1507 ... for the Treatment of ... today that its partner, Roche has initiated a Phase II,clinical study ... antibody was created by Genmab under the company,s,agreement with Roche and ...
Cached Biology Technology:Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant 2Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant 3Reliant Pharmaceuticals Announces the Filing of Registration Statement on Form S-1 For an Initial Public Offering 2Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma 2
(Date:10/28/2014)... Individual differences in moving activity in a novel ... to angling, according to an experimental study completed ... Finnish Game and Fisheries Research Institute. The study ... groups and authentic angling trials to analyse if ... trout reared in traditional and enriched hatchery rearing ...
(Date:10/27/2014)... a scientific one-two punch with a pair of papers ... sticky ends. , Collagen is the most common protein ... fibrous tissues that support cells and hold organs together. ... for tissue engineering and cosmetic and reconstructive medicine. , ... synthetic collagen for a decade, teasing out the details ...
(Date:10/27/2014)... day, about a third of blacks hold onto sodium ... an hour after the stress that raised their pressure ... know how chronic mental stress, obesity, and inflammation conspire ... the best ways to treat it. , "We ... – these patients have increased damage to their hearts, ...
Breaking Biology News(10 mins):Fish 'personality' linked to vulnerability to angling 2'Sticky' ends start synthetic collagen growth 2'Sticky' ends start synthetic collagen growth 3Researchers look for the best way to help shake too much sodium 2Researchers look for the best way to help shake too much sodium 3Researchers look for the best way to help shake too much sodium 4
... one of many important crop species that is unsuited ... used to work with crops. Researchers, reporting in the ... first high-throughput forward and reverse genetics tool for the ... breeders around the world.. Researchers from the INRA ...
... ambitious expedition led by scientists at Scripps Institution of ... little-known islands in the central Pacific Ocean has yielded ... threats from human activities. The exploration of four ... approximately a thousand miles south of Hawaii, has produced ...
... The reductionist goal of cell biology is to ... do this, one needs to quantify molecular concentrations ... execute and regulate various complex processes. For ... characterized by highly localized, transient component processes, the ...
Cached Biology News:Scientists unravel the genetic coding of the pea 2Scripps expedition provides new baseline for coral reef conservation 2Scripps expedition provides new baseline for coral reef conservation 3
... effect inhibition assays, also known as CPE and ... supernatents; serum from PK studies and delivery formulations. ... as the quantity of interferon required per milliliter ... by 50%. All standards used in ...
... is a type I eukaryotic topoisomerase that ... (also called right- and left-handed supercoils) from ... reaction is a covalently closed, circular DNA ... DNA Topoisomerase I does not absolutely require ...
... Topoisomerase I from vaccinia virus is a ... positive and negative superhelical turns (also called ... DNA. The product of the reaction is ... positive or negative superhelical turns. DNA Topoisomerase ...
... DNA Modification Kit contains reagents required to ... sample. In the bisulfite reaction, all unmethylated ... to uracils, while 5-methylcytosines remain unaltered. Thus, ... differ depending on whether the DNA is ...
Biology Products: